🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Lacuna Pharma Pty Ltd

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  2. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  3. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  4. RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect

    Advanced Accelerator Applications

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial

  6. RAP-219

    Rapport Therapeutics

    Focal Seizure

    phase 3 small molecule active

    2 trials

  7. RAPIBLOC 300 mg, poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  8. RECOMBINANT ADAMTS13 (rADAMTS13), RECOMBINANT ADAMTS13 (rADAMTS13)

    Baxalta Innovations GmbH

    Congenital Thrombotic thrombocytopenic purpura (cTTP)

    phase 3 small molecule active

    1 trial

  9. REGN10933 + REGN10987

    Regeneron UK Limited

    Healthy Participants

    phase 3 small molecule completed

    1 trial

  10. REGN1908

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule completed

    1 trial

  11. REGN1908-1909

    Regeneron UK Limited

    Allergic Rhinitis Due to Cat Allergy

    phase 3 small molecule terminated

    1 trial

  12. REGN2810

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  13. REGN2810/ipi

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  14. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  15. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  16. REGN5713

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule active

    2 trials

  17. REGN5713

    Regeneron UK Limited

    Allergic Rhinitis

    phase 3 small molecule completed

    2 trials

  18. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  19. REL-1017

    RELMADA THERAPEUTICS, INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  20. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  21. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  22. RHB-102

    RedHill Biopharma

    Gastroenteritis

    phase 3 small molecule completed

    1 trial

  23. RHB-104

    RedHill Biopharma

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  24. RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources